Phaseline

Targets › PLAUR

PLAUR (Urokinase plasminogen activator surface receptor): drug programs, companies and trials

2 programs from 2 companies in 2 trials: 1 Phase 2, 1 Phase 1; Oncology; next expected readout Jan 2027.

GPI-anchored receptor that recruits and activates the urokinase-type plasminogen activator (uPA) at the cell surface. Activated uPA converts plasminogen into plasmin, initiating extracellular matrix degradation and remodeling. (UniProt, Q03405)

Open in Phaseline: the race on PLAUR, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Curasight64Cu-DOTA-AE105
uPAR-targeting PET imaging agent; copper-64 labeled peptide for PET imaging of uPAR-expres
PLAURPhase 2Prostate CancerJan 2027
Adcendo ApSADCE-D01
anti-uPARAP antibody conjugated to topoisomerase I inhibitor via protease-cleavable linker
PLAURPhase 1Metastatic Soft Tissue SarcomaFeb 2029

Conditions

Prostate Cancer (1) Metastatic Soft Tissue Sarcoma (1)

Modalities

small molecule (1), antibody (1)

Companies

Curasight (1) Adcendo ApS (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.